Roche Holding AG (RHHVF)
OTCMKTS · Delayed Price · Currency is USD
338.60
+3.08 (0.92%)
Sep 11, 2025, 2:52 PM EDT
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$773,189
Profits / Employee
$114,831
Market Cap
289.56B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| CytoDyn | 13 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
Roche Holding AG News
- 6 days ago - Roche Holding AG (RHHBY) Gains CE-IVDR Approval for VENTANA HER2 (4B5) Test | RHHBY stock news - GuruFocus
- 6 days ago - New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or ... - GuruFocus
- 6 days ago - Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify ... - GuruFocus
- 6 days ago - Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients - PRNewsWire
- 6 days ago - New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD) - GlobeNewsWire
- 6 days ago - New Data for Genentech's Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD) - Business Wire
- 7 days ago - Roche gets EU CE mark for its Port Delivery platform containing Susvimo - Seeking Alpha
- 7 days ago - Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD) - GlobeNewsWire